Nvax stock price climbed 2

NVAX stock price climbed 2.3% to $4.69 in morning trading on optimism around global vaccine partnerships. Market analysts believe any positive clinical trial data could catalyze a breakout above $5, a resistance zone NVAX has struggled to cross since November. Bad Bunny Used His Saturday Night Live Gig to Roast MAGA Shares of Novavax rose nearly 13% yesterday, attributable to this transition. A pharma giant like Sanofi, which already has a well-built distribution and commercial supply chain across the globe, is likely better placed to market Nuvaxovid than the company for the current vaccination season. NVAX stock price recently showed heightened volatility, trading near $4.58 in midday market action, down 3.5% from last session. Analysts note investor sentiment is mixed ahead of upcoming Q4 earnings, with biotech sector momentum heavily influencing NVAX’s short-term trajectory. Volume trends are above the 30-day average, indicating active speculation.